Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | KIT | P10721 | 2/20 | 0.32 |
| ▸ | FLT1 | P17948 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6733594 | 0.94 | HRH3 (0.37) | HRH3KITFLT1KDRPTGER4 | |
| SCHEMBL6729180 | 0.88 | HRH3 (0.38) | HRH3MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL6734818 | 0.88 | HRH3 (0.38) | HRH3MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL6736330 | 0.86 | HRH3 (0.43) | HRH3MEN1KMT2ACYP2D6CYP2C9 | |
| SCHEMBL6739327 | 0.84 | HRH3 (0.41) | HRH3MEN1KMT2ACYP2D6CYP2C9 | |
| SCHEMBL6735891 | 0.83 | HRH3 (0.42) | HRH3CYP2D6CYP2C9 | |
| SCHEMBL6734154 | 0.83 | HRH3 (0.42) | HRH3CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6730287 | 0.83 | HRH3 (0.42) | HRH3CYP2D6CYP2C9 | |
| SCHEMBL6735021 | 0.83 | HRH3 (0.34) | HRH3 | |
| SCHEMBL6734830 | 0.83 | CYP2D6 (0.46) | HRH3CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040122026-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20030225288-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HRH3 530/4885KIT 2203/4885FLT1 3807/4885 |
| US-20030225288-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HRH3 530/4885KIT 2203/4885FLT1 3807/4885 |
| US-20040122026-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HRH3 530/4885KIT 2203/4885FLT1 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.